GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cyclacel Pharmaceuticals Inc (NAS:CYCC) » Definitions » 6-1 Month Momentum %

Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) 6-1 Month Momentum %

: -74.04% (As of Today)
View and export this data going back to 2006. Start your Free Trial

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-16), Cyclacel Pharmaceuticals's 6-1 Month Momentum % is -74.04%.

The industry rank for Cyclacel Pharmaceuticals's 6-1 Month Momentum % or its related term are showing as below:

CYCC's 6-1 Month Momentum % is ranked worse than
95.52% of 1518 companies
in the Biotechnology industry
Industry Median: -3.04 vs CYCC: -74.04

Competitive Comparison

For the Biotechnology subindustry, Cyclacel Pharmaceuticals's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cyclacel Pharmaceuticals 6-1 Month Momentum % Distribution

For the Biotechnology industry and Healthcare sector, Cyclacel Pharmaceuticals's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Cyclacel Pharmaceuticals's 6-1 Month Momentum % falls into.



Cyclacel Pharmaceuticals  (NAS:CYCC) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %=( Price 1-month ago / Price 6-month ago - 1 ) * 100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cyclacel Pharmaceuticals  (NAS:CYCC) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.


Cyclacel Pharmaceuticals 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Cyclacel Pharmaceuticals's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cyclacel Pharmaceuticals (Cyclacel Pharmaceuticals) Business Description

Traded in Other Exchanges
Address
200 Connell Drive, Suite 1500, Berkeley Heights, NJ, USA, 07922
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company which develops targeted medicines for cancer and other proliferative diseases. It develops several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK (cyclin dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.
Executives
Spiro Rombotis director, officer: President & C.E.O. C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Paul Mcbarron director, officer: E.V.P., Finance & C.O.O. C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500, BERKELEY HEIGHTS NJ 07922
Kenneth M. Ferguson director 2125 1ST AVENUE #2902, SEATTLE WA 98121-2121
Sam L Barker director 51 AUNT MOLLY ROAD, HOPEWELL NJ 08525
Brian Schwartz director C/O ARQULE, INC., 1 WALL STREET, 6TH FLOOR, BURLINGTON MA 01803
Karin L Walker director C/O PROTHENA CORPORATION PLC, 650 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Mark Kirschbaum officer: Chief Medical Officer 66 WEST 38TH STREET, APT. 19D, NEW YORK NY 10018
Robert J. Spiegel director C/O GERON CORPORATION, 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Eastern Capital Ltd 10 percent owner 10 MARKET STREET, #773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kevin C Tang 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Partners Lp 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Tang Capital Management Llc 10 percent owner 4747 EXECUTIVE DRIVE, SUITE 210, SAN DIEGO CA 92121
Portfolio Services Ltd. 10 percent owner 10 MARKET STREET, # 773, CAMANA BAY, GRAND CAYMAN E9 KY1-9006
Kenneth Bryan Dart 10 percent owner P. O. BOX 31300, GRAND CAYMAN E9 KY1-1206
Lloyd Sems director C/O SEMS CAPITAL, 7 DEY STREET, SUITE 1101, NEW YORK NY 10017